6386-24-9

Basic information

• Product Name: 2,3,4,6-TETRA-O-BENZYL-D-GALACTOPYRANOSE
• Synonyms: TETRA-O-BENZYL-D-GALACTOPYRANOSE;2,3,4,6-Tetrakis-O-(phenylmethyl)-D-galactopyranose;(3R,4S,5S,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-ol
• CAS NO: 6386-24-9
• Molecular Formula: C₃₄H₃₆O₆
• Molecular Weight: 540.65
• Mol File: 6386-24-9.mol
• Article Data: 189

Chemical Properties

• Melting Point: 64-69°C
• Boiling Point: 672.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• Storage Temp.: ?20°C
• PKA: 11.87±0.70(Predicted)
• CAS DataBase Reference: 2,3,4,6-TETRA-O-BENZYL-D-GALACTOPYRANOSE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,6-TETRA-O-BENZYL-D-GALACTOPYRANOSE(6386-24-9)
• EPA Substance Registry System: 2,3,4,6-TETRA-O-BENZYL-D-GALACTOPYRANOSE(6386-24-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 6386-24-9(Hazardous Substances Data)

Usage

General Description

2,3,4,6-Tetra-O-benzyl-D-galactopyranose is a chemical compound with the molecular formula C34H34O5. It is a derivative of galactopyranose, a six-membered ring sugar molecule. The compound is commonly used as a protecting group for the hydroxyl groups of sugars, which allows for selective modification of other functional groups within the molecule. 2,3,4,6-TETRA-O-BENZYL-D-GALACTOPYRANOSE has applications in organic synthesis, particularly in the preparation of complex carbohydrate molecules for use in pharmaceutical research and drug development. Additionally, it is used in the synthesis of glycosides, which are important molecules in various biological processes.

Upstream product

• 13096-63-4 2,3,4,6-Tetra-O-benzyl-N,N-dimethyl-D-gluconamid 
• 3879-79-6 methyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside 
• 56822-49-2 1-O-acetyl-2,3,4,6-tetra-O-benzyl-D-glucopyranoside 
• 115969-49-8 2-(trimethylsilyl)ethyl 2,3,4,6-tetra-O-benzyl-β-D-glucopyranoside 
• 128785-05-7 Dimethyl-phenyl-((2S,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxymethyl)-silane 
• 74352-41-3 2-Pyridyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-galactopyranoside 
• 134003-35-3 pent-4-enyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside 
• 136215-68-4 2,3,4,6,1',3',4'-hepta-O-benzyl-6'-O-tert-(butyldiphenylsilyl)sucrose 
• 139212-74-1 N-sodio-N'-(2,3,4,6-tetra-O-benzyl-D-glucopyranosylidene)-4-toluenesulfonohydrazidate 
• 150-76-5 4-methoxy-phenol 
• 6207-45-0 2-(allyloxy)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran 
• 78136-20-6 (2R,3S,4S)-2,3,4,6-Tetrakis-benzyloxy-5-(tert-butyl-dimethyl-silanyloxy)-hexanal 
• 78136-20-6 2,3,4,6-tetra-O-benzyl-5-O-(tert-butyldimethylsilyl)-L-idose 
• 117253-13-1 2-(trimethylsilyl)ethyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside 

Downstream Products

• 74808-06-3 O-(2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyl)-N,2,2-triphenylacetimidat 
• 85422-87-3 1-phenyl-2-((2R,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)ethan-1-one 
• 116417-79-9 phthalimidyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside 
• 116417-80-2 phthalimidyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside 
• 92812-56-1 benzyl O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-(1->6)-4-O-allyl-2,3-di-O-benzyl-α-D-glucopyranoside 
• 82805-19-4 benzyl O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-(1->6)-4-O-allyl-2,3-di-O-benzyl-α-D-glucopyranoside 
• 83921-84-0 ethyl O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-(1<*>6)-2,3,4-tri-O-benzyl-1-thio-α-D-glucopyranoside 
• 83906-38-1 benzyl O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-(1->6)-2,3,4-tri-O-benzyl-α-D-glucopyranoside 
• 74352-41-3 2-Pyridyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-galactopyranoside 
• 144490-57-3 2-pyridyl 2,3,4,6-tetra-O-benzyl-1-thio-αβ-D-glucopyranoside 
• 30608-21-0 1-O-trimethylsilyl-2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside 
• 82561-63-5 2,3,4,6-Tetra-O-benzyl-1-O-β-D-glucopyranose 
• 82110-05-2 1,5-di-O-acetyl-2,4,6-tri-O-benzyl-2-dehydro-3-deoxy-D-erythro-hex-2(Z)-enitol 
• 77637-99-1 1,5-di-O-acetyl-2,3,4,6-tetra-O-benzyl-D-glucitol 

Relevant articles and documents

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

Regioselective Anomeric O-Benzyl Deprotection in Carbohydrates

A highly regioselective hydrogenolysis of the anomeric benzyl group is reported. The reaction involves selective acetolysis of benzyl acetals of various mono- and di-saccharides using 10 % Pd/C under hydrogen atmosphere in the presence of Na2CO

Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors

We have designed unprecedented cholinesterase inhibitors based on 1-deoxynojirimycin as potential anti-Alzheimer’s agents. Compounds are comprised of three key structural motifs: the iminosugar, for interaction with cholinesterase catalytic anionic site (